*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
How we score providers
Every provider is scored against the published v3.0 six-pillar rubric (100 points total), applied uniformly. Read the full methodology →
All 10 providers reviewed
NexLife — 94/100
Rank
#1 of 10
Score
94/100 (4.7/5 stars)
Pillars met
6 of 6
Pricing
$145-$165/mo
Pharmacy
503A & 503B
Model
MD/DO-led
The only provider in our directory that publishes against all six transparency pillars for semaglutide. Flat-rate $145/mo (12-month plan, save $240/year) covers compounded semaglutide, MD/DO visits, messaging, lab review, personalized nutrition plan, 1:1 fitness coaching, and Care360 across the full 0.25-2.4 mg titration. Klarna and Afterpay financing accepted.
Brand-name Wegovy and Ozempic through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
Compounded semaglutide via async NP-led intake. Single pillar met (clinical protocol). Async-only model and limited pharmacy traceability are the key gaps.
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy via insurance). Behavioral-program integration is the differentiator.
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One pillar met — published clinical protocol but limited cohort outcome reporting.
Insurance-billing brand telehealth. $0 patient cost when in-network. Two pillars met. Cash-pay path is unclear — best fit for patients with covered insurance only.
Mixed model — branded GLP-1s plus compounded options. Zero pillars met against our v3.0 rubric due to limited public disclosure on pharmacy and outcomes.
